Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 10/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24806799 | 0.83 | CHRNB4 (0.45) | CHRNB4CHRNA3HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL6937125 | 0.83 | OPRM1 (0.37) | CHRNB4CHRNA3HSD17B1HSD17B2OPRD1 | |
| SCHEMBL6934582 | 0.81 | HRH3 (0.36) | CHRNB4CHRNA3OPRD1 | |
| SCHEMBL6934469 | 0.80 | OPRM1 (0.41) | HSD17B1HSD17B2OPRD1 | |
| Hydrochloric Acid SCHEMBL7872718 | 0.80 | OPRM1 (0.37) | CHRNB4CHRNA3OPRD1 | |
| SCHEMBL6934590 | 0.80 | DRD3 (0.41) | — | |
| SCHEMBL6933172 | 0.80 | OPRM1 (0.38) | CHRNB4CHRNA3OPRD1 | |
| SCHEMBL7752297 | 0.79 | MAOB (0.41) | HSD17B2ALDH1A1 | |
| SCHEMBL6934080 | 0.79 | OPRK1 (0.40) | HSD17B1HSD17B2OPRD1 | |
| Hydrochloric Acid SCHEMBL7870812 | 0.79 | OPRM1 (0.39) | CHRNB4CHRNA3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563758-A1 | NEW COMPOUNDS, SYNTHESIS AND USE THEREOF IN THE TREATMENT OF PAIN | LACER, S.A. (ES) | 2013-03-06 | — | — | EP | disclosed |
| US-20130046012-A1 | NEW COMPOUNDS, SYNTHESIS AND USE THEREOF IN THE TREATMENT OF PAIN | LACER, S.A. (ES) | 2013-02-21 | — | — | US | disclosed |
| WO-2011135007-A1 | NEW COMPOUNDS, SYNTHESIS AND USE THEREOF IN THE TREATMENT OF PAIN | LACER, S.A. (ES) | 2011-11-03 | — | — | WO | disclosed |
| EP-2383255-A1 | New compounds, synthesis and use thereof in the treatment of pain | LACER, S.A. (ES) | 2011-11-02 | — | — | EP | disclosed |
| EP-1219594-B1 | New esters derived from substituted phenyl-cyclohexyl compounds | VITA LAB (ES) | 2004-01-14 | — | — | EP | disclosed |
| EP-1127871-B1 | NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS | VITA LAB (ES) | 2003-09-10 | — | — | EP | disclosed |
| US-20030100598-A1 | Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | LABORATORIOS VITA, S.A. (ES) | 2003-05-29 | — | — | US | disclosed |
| US-6455585-B1 | HAVE A HIGHER ANALGESIC ACTIVITY, A LOWER TOXICITY AND A LONGER EFFECTIVE TIME PERIOD THAN TRAMADOL. | VITA INVEST, S.A. (ES) | 2002-09-24 | — | — | US | disclosed |
| EP-1219594-A1 | New esters derived from substituted phenyl-cyclohexyl compounds | VITA-INVEST, S.A. (ES) | 2002-07-03 | — | — | EP | disclosed |
| EP-1127871-A1 | NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS | VITA-INVEST, S.A. (ES) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046012-A1 | NEW COMPOUNDS, SYNTHESIS AND USE THEREOF IN THE TREATMENT OF PAIN | OPRL1, OPRK1, TRPV1 | CHRNB4 1871/4885CHRNA3 1612/4885HSD17B1 743/4885 |
| US-20030100598-A1 | Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | OPRK1, CYP2E1, OPRD1 | CHRNB4 1124/4885CHRNA3 1737/4885HSD17B1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.